Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

Blue­bird bio $BLUE has picked up an op­tion to co-pro­mote and co-de­vel­op its close­ly-watched an­ti-BC­MA CAR-T bb2121 for mul­ti­ple myelo­ma pa­tients along­side Cel­gene $CELG.

Hav­ing worked to­geth­er over the past 5 years, blue­bird says it will cov­er half of the de­vel­op­ment costs for bb2121, be­gin­ning in April, while look­ing to split the prof­its it gen­er­ates in the US. Cel­gene is in con­trol out­side the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.